tiprankstipranks
Incyte Corp (INCY)
NASDAQ:INCY

Incyte (INCY) Stock Price & Analysis

1,536 Followers

INCY Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$50.27 - $67.37
Previous Close$57.1
Volume1.62M
Average Volume (3M)2.02M
Market Cap
$12.82B
Enterprise Value$9.20B
Total Cash (Recent Filing)$3.66B
Total Debt (Recent Filing)$32.60M
Price to Earnings (P/E)17.3
Beta0.63
Jul 30, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.29
Shares Outstanding224,540,751
10 Day Avg. Volume2,707,754
30 Day Avg. Volume2,016,164
Standard Deviation0.08
R-Squared0.19
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.60
Price to Sales (P/S)12.65
Price to Cash Flow (P/CF)21.60
P/FCF Ratio21.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.58
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda9.31
Forecast
Price Target Upside24.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15

Bulls Say, Bears Say

Bulls Say
Pipeline DevelopmentAxatilimab has a high probability of gaining FDA approval, with a 63.5% ORR in the AGAVE-201 trial.
Stock BuybackThe share buyback reflects management's conviction that the share price is undervalued, providing a fundamental boost to free cash flow per share.
Strategic AcquisitionIncyte's acquisition of Escient Pharmaceuticals includes promising clinical-stage molecules with potential data by early 2025.
Bears Say
CompetitionIncreasing competitive pressure could impact Jakafi sales.
Financial PerformanceIncyte missed consensus on key product revenues, with Jakafi sales significantly underperforming expectations.
Investment StrategyThe stock buyback is not viewed as the most efficient use of capital.
---

Financials

Annual

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

INCY FAQ

What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was $50.27 and its highest was $67.36 in the past 12 months.
    What is Incyte Corp’s market cap?
    Currently, no data Available
    When is Incyte Corp’s upcoming earnings report date?
    Incyte Corp’s upcoming earnings report date is Jul 30, 2024 which is in 72 days.
      How were Incyte Corp’s earnings last quarter?
      Incyte Corp released its earnings results on Apr 30, 2024. The company reported $0.643 earnings per share for the quarter, missing the consensus estimate of $0.798 by -$0.155.
        Is Incyte Corp overvalued?
        According to Wall Street analysts Incyte Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Incyte Corp pay dividends?
          Incyte Corp does not currently pay dividends.
          What is Incyte Corp’s EPS estimate?
          Incyte Corp’s EPS estimate is $1.07.
            How many shares outstanding does Incyte Corp have?
            Incyte Corp has 224,540,760 shares outstanding.
              What happened to Incyte Corp’s price movement after its last earnings report?
              Incyte Corp reported an EPS of $0.643 in its last earnings report, missing expectations of $0.798. Following the earnings report the stock price went down -0.97%.
                Which hedge fund is a major shareholder of Incyte Corp?
                Among the largest hedge funds holding Incyte Corp’s share is Baker Bros Advisors LP. It holds Incyte Corp’s shares valued at 2B.
                  ---

                  Company Description

                  Incyte Corp

                  Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
                  ---

                  INCY Company Deck

                  ---

                  INCY Earnings Call

                  Q1 2024
                  0:00 / 0:00
                  ---

                  INCY Revenue Breakdown

                  85.65%85.65%14.16%0.19%
                  85.65% Product revenues, net
                  14.16% Product royalty revenues
                  0.19% Milestone and contract revenues
                  tipranks
                  ---

                  INCY Stock 12 Month Forecast

                  Average Price Target

                  $71.18
                  ▲(24.66% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"51":"$51","86":"$86","59.75":"$59.8","68.5":"$68.5","77.25":"$77.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$85.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":71.18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$71.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$52.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[51,59.75,68.5,77.25,86],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.76,56.16307692307692,58.566153846153846,60.96923076923077,63.37230769230769,65.77538461538461,68.17846153846153,70.58153846153846,72.98461538461538,75.3876923076923,77.79076923076923,80.19384615384615,82.59692307692308,{"y":85,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.76,55.1,56.44,57.78,59.120000000000005,60.46,61.800000000000004,63.14,64.48,65.82000000000001,67.16000000000001,68.5,69.84,{"y":71.18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.76,53.62461538461538,53.489230769230765,53.35384615384615,53.21846153846154,53.08307692307692,52.94769230769231,52.81230769230769,52.676923076923075,52.54153846153846,52.40615384615385,52.27076923076923,52.135384615384616,{"y":52,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.57,"date":1684454400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.54,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.07,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.63,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.69,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.33,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.85,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.02,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.26,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.35,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.05,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.24,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.76,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Gilead Sciences
                  Bristol-Myers Squibb
                  Amgen
                  Biogen

                  Best Analysts Covering INCY

                  1 Year
                  Marc FrahmTD Cowen
                  1 Year Success Rate
                  17/24 ratings generated profit
                  71%
                  1 Year Average Return
                  +8.97%
                  reiterated a buy rating 18 days ago
                  Copying Marc Frahm's trades and holding each position for 1 Year would result in 70.83% of your transactions generating a profit, with an average return of +8.97% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis